GSK pulls one lot of Infanrix vaccine on contamination worries; Irish output sinks on 35% drop in pharma production;

@FiercePharma: Are you ready, Humira? Pfizer nabs FDA blessing for blockbuster hopeful Xeljanz, for rheumatoid arthritis. Story | Follow @FiercePharma

> GlaxoSmithKline ($GSK) pulled another lot of its Infanrix Hexa vaccine because of potential microbial contamination; the recall follows a similar move in Australia. Report

> Pharma cuts in Ireland are taking their toll; the country's manufacturing output dropped 14% as drugmakers' production dropped by 35%. Report

> Sanofi ($SNY) CEO Christopher Viehbacher was elected president of EFPIA, Europe's pharma trade group, where he will replace GlaxoSmithKline Chief Andrew Witty. Report

> Sanofi priced a new bond issue, aiming to raise €750 million ($957 million) from the sale. Report

> Canada's top court is preparing to decide whether Pfizer's ($PFE) Viagra patent is valid, in a case that could sway patent law toward--or away from--transparency, experts say. Report

> The Taro Pharmaceuticals ($TARO) feud with Sun Pharma continues with accusations of under-reported sales, as Taro shareholders prepare to vote on a proposed merger with the Indian company. Report

Medical Device News

 @FierceMedDev: BSX study shows improved defibrillator programming reduces unnecessary jolts as well as risk of death. More | Follow @FierceMedDev

 @MarkHFierce: BD ended its 2012 fiscal year on a down note. But CE Forlenza qualifies it as a "solid finish." News | Follow @MarkHFierce

 @DamianFierce: Medical device manufacturer Onyx got snapped up for $43.25M by Sparton. Story | Follow @DamianFierce

> Mindray tanks on disappointing Q3. Article

> Medtronic-backed study supports greater use of CRT pacemakers. Story

> Study: Valves & stents often win FDA nod without proving they improve care. Item

Biotech News

 @FierceBiotech: Test could detect a range of cancers weeks before symptoms. More | Follow @FierceBiotech

 @JohnCFierce: Are clinical trial investigators guilty of mission creep? Report | Follow @JohnCFierce

 @RyanMFierce: Maverix enters genomics software game with Silicon Valley sizzle. More | Follow @RyanMFierce

> Roche, ImmunoGen gain speedy review for T-DM1 breast cancer breakthrough. News

> FDA hands Pfizer blockbuster approval for rheumatoid arthritis drug tofacitinib. Story

Drug Delivery News

> Hydrogel time bombs set off explosive drug release. Story

> Novartis submits COPD combination inhaler in Japan. Item

> $1M Gates Foundation grant to formulate lifesaving oxytocin. News

Biomarkers News

> Bowel cancer biomarkers from Down Under catch U.S. attention. Item

> Blood protein tags progression in ALS. Article

> Phase III finding points to masitinib CDx for pancreatic cancer. Story

> Breast cancer biomarkers predict tamoxifen response. Report

> Simple blood count points to survival in aggressive skin cancer. News

And Finally... Performance-enhancing drugs aren't limited to athletes, creating ethical dilemmas at the office. Report

 

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.